NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, February, 14th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.08. The biotechnology company had revenue of $44.86 million for the quarter, compared to the consensus estimate of $29.24 million. View ImmunoGen's Earnings History.

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, May 1st 2020. View Earnings Estimates for ImmunoGen.

ImmunoGen issued an update on its FY 2020 Pre-Market earnings guidance on Friday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $44.62 million.

9 analysts have issued 1-year price objectives for ImmunoGen's stock. Their forecasts range from $2.50 to $9.00. On average, they anticipate ImmunoGen's stock price to reach $4.28 in the next year. This suggests that the stock has a possible downside of 20.4%. View Analyst Price Targets for ImmunoGen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ImmunoGen.

News headlines about IMGN stock have been trending positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ImmunoGen earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for ImmunoGen.

ImmunoGen saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 12,550,000 shares, an increase of 14.2% from the December 31st total of 10,990,000 shares. Based on an average daily volume of 2,430,000 shares, the short-interest ratio is currently 5.2 days. Approximately 8.5% of the shares of the company are short sold. View ImmunoGen's Current Options Chain.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Micron Technology (MU), Pfizer (PFE), Exelixis (EXEL), NVIDIA (NVDA), Advanced Micro Devices (AMD), Nektar Therapeutics (NKTR), AbbVie (ABBV), Gilead Sciences (GILD) and Alibaba Group (BABA).

ImmunoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.15%), Palo Alto Investors LP (3.96%), State Street Corp (3.57%), Geode Capital Management LLC (1.62%), Panagora Asset Management Inc. (1.41%) and Pinnacle Associates Ltd. (0.85%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View Institutional Ownership Trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, SG Americas Securities LLC, Rafferty Asset Management LLC, Bank of America Corp DE, Pinnacle Associates Ltd., Stifel Financial Corp and Raymond James & Associates. Company insiders that have sold ImmunoGen company stock in the last year include Mark J Enyedy and Thomas Ryll. View Insider Buying and Selling for ImmunoGen.

IMGN stock was bought by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc., Panagora Asset Management Inc., Public Sector Pension Investment Board, Jacobs Levy Equity Management Inc. and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $5.38.

ImmunoGen has a market capitalization of $804.64 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.View Additional Information About ImmunoGen.

The official website for ImmunoGen is http://www.immunogen.com/.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]